dc.contributor.author |
Dos Santos G.A.S. |
dc.contributor.author |
Abreu E Lima R.S. |
dc.contributor.author |
Pestana C.R. |
dc.contributor.author |
Lima A.S.G. |
dc.contributor.author |
Scheucher P.S. |
dc.contributor.author |
Thome C.H. |
dc.contributor.author |
Gimenes-Teixeira H.L. |
dc.contributor.author |
Santana-Lemos B.A.A. |
dc.contributor.author |
Lucena-Araujo A.R. |
dc.contributor.author |
Rodrigues F.P. |
dc.contributor.author |
Nasr R. |
dc.contributor.author |
Uyemura S.A. |
dc.contributor.author |
Falcao R.P. |
dc.contributor.author |
De The H. |
dc.contributor.author |
Pandolfi P.P. |
dc.contributor.author |
Curti C. |
dc.contributor.author |
Rego E.M. |
dc.contributor.editor |
|
dc.date |
Mar-2012 |
dc.date.accessioned |
2017-10-05T15:41:34Z |
dc.date.available |
2017-10-05T15:41:34Z |
dc.date.issued |
2012 |
dc.identifier |
10.1038/leu.2011.216 |
dc.identifier.isbn |
|
dc.identifier.issn |
08876924 |
dc.identifier.uri |
http://hdl.handle.net/10938/18057 |
dc.description.abstract |
The vitamin E derivative (+)α-tocopheryl succinate (α-TOS) exerts pro-apoptotic effects in a wide range of tumors and is well tolerated by normal tissues. Previous studies point to a mitochondrial involvement in the action mechanism; however, the early steps have not been fully elucidated. In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RARα transgenic mice, we demonstrated that α-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy. We also demonstrated that α-TOS induces an early dissipation of the mitochondrial membrane potential in APL cells and studies with isolated mitochondria revealed that this action may result from the inhibition of mitochondrial respiratory chain complex I. Moreover, α-TOS promoted accumulation of reactive oxygen species hours before mitochondrial cytochrome c release and caspases activation. Therefore, an in vivo antileukemic action and a novel mitochondrial target were revealed for α-TOS, as well as mitochondrial respiratory complex I was highlighted as potential target for anticancer therapy. © 2012 Macmillan Publishers Limited All rights reserved. |
dc.format.extent |
|
dc.format.extent |
Pages: (451-460) |
dc.language |
English |
dc.publisher |
LONDON |
dc.relation.ispartof |
Publication Name: Leukemia; Publication Year: 2012; Volume: 26; no. 3; Pages: (451-460); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo |
dc.type |
Article |
dc.contributor.affiliation |
Dos Santos, G.A.S., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil, Department of Physics and Chemistry, Pharmaceutical Sciences Faculty of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil |
dc.contributor.affiliation |
Abreu E Lima, R.S., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Pestana, C.R., Department of Physics and Chemistry, Pharmaceutical Sciences Faculty of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil |
dc.contributor.affiliation |
Lima, A.S.G., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Scheucher, P.S., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Thomé, C.H., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Gimenes-Teixeira, H.L., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Santana-Lemos, B.A.A., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Lucena-Araujo, A.R., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
Rodrigues, F.P., Department of Physics and Chemistry, Pharmaceutical Sciences Faculty of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil |
dc.contributor.affiliation |
Nasr, R., Department of Internal Medicine, American University of Beirut, Beirut, Lebanon, CNRS Unité Mixte de Recherche (UMR) 7151, Laboratoire Associé Au Comité de Paris de la Ligue Contre Le Cancer, Paris, France |
dc.contributor.affiliation |
Uyemura, S.A., Department of Clinical, Toxicological and Bromatological Analysis, Pharmaceutical Sciences Faculty of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil |
dc.contributor.affiliation |
Falcão, R.P., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.affiliation |
De Thé, H., CNRS Unité Mixte de Recherche (UMR) 7151, Laboratoire Associé Au Comité de Paris de la Ligue Contre Le Cancer, Paris, France |
dc.contributor.affiliation |
Pandolfi, P.P., Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States |
dc.contributor.affiliation |
Curti, C., Department of Physics and Chemistry, Pharmaceutical Sciences Faculty of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil |
dc.contributor.affiliation |
Rego, E.M., Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil |
dc.contributor.authorAddress |
Rego, E.M.; Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Av. Bandeirantes 3900, 14048-900 Ribeirão Preto, São Paulo, Brazil; email: emrego@hcrp.fmrp.usp.br |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
emrego@hcrp.fmrp.usp.br |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
dos Santos, GAS |
dc.contributor.authorInitials |
Lima, RSAE |
dc.contributor.authorInitials |
Pestana, CR |
dc.contributor.authorInitials |
Lima, ASG |
dc.contributor.authorInitials |
Scheucher, PS |
dc.contributor.authorInitials |
Thome, CH |
dc.contributor.authorInitials |
Gimenes-Teixeira, HL |
dc.contributor.authorInitials |
Santana-Lemos, BAA |
dc.contributor.authorInitials |
Lucena-Araujo, AR |
dc.contributor.authorInitials |
Rodrigues, FP |
dc.contributor.authorInitials |
Nasr, R |
dc.contributor.authorInitials |
Uyemura, SA |
dc.contributor.authorInitials |
Falcao, RP |
dc.contributor.authorInitials |
de The, H |
dc.contributor.authorInitials |
Pandolfi, PP |
dc.contributor.authorInitials |
Curti, C |
dc.contributor.authorInitials |
Rego, EM |
dc.contributor.authorOrcidID |
Uyemura, Sergio-0000-0001-5505-9817; Rego, Eduardo-0000-0003-1567-4086; Teixeira, Hamilton-0000-0001-6531-8587; |
dc.contributor.authorReprintAddress |
Rego, EM (reprint author), Univ Sao Paulo, Div Hematol Oncol, Natl Inst Sci and Technol Cell Based Therapy, Dept Internal Med,Med Sch Ribeirao Preto, Av Bandeirantes 3900, BR-14048900 Sao Paulo, Brazil. |
dc.contributor.authorResearcherID |
Uyemura, Sergio-B-4656-2011; Pestana, Cezar-K-6250-2012; Rego, Eduardo-A-1058-2012; Teixeira, Hamilton-E-5602-2013; Scheucher, Priscila-F-1599-2013; Celulas tronco, Inct-I-1921-2013; Terapia celular, Cepid-I-4398-2013; Inov Farmaceutica, Inct-K-2313-2013; |
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Arnoult D, 2008, METHODS, V44, P229, DOI 10.1016-j.ymeth.2007.11.003; Basu A, 2007, EUR J NUTR, V46, P34, DOI 10.1007-s00394-006-0629-4; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016-j.ccr.2006.10.020; Campbell AM, 2008, J BIOENERG BIOMEMBR, V40, P193, DOI 10.1007-s10863-008-9138-x; Diaz Z, 2007, LEUKEMIA, V21, P2117, DOI 10.1038-sj.leu.2404891; Diaz Z, 2005, BLOOD, V105, P1237, DOI 10.1182-blood-200405-1772; Dong LF, 2009, CLIN CANCER RES, V15, P1593, DOI 10.1158-1078-0432.CCR-08-2439; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038-onc.2008.69; Fariss MW, 2001, FREE RADICAL BIO MED, V31, P530, DOI 10.1016-S0891-5849(01)00615-3; Forghieri F, 2009, LEUKEMIA LYMPHOMA, V50, P119, DOI 10.1080-10428190802535106; Freitas RA, 2009, LEUKEMIA RES, V33, P958, DOI 10.1016-j.leukres.2008.09.035; Grivennikova VG, 2006, BBA-BIOENERGETICS, V1757, P553, DOI 10.1016-j.bbabio.2006.03.013; Guibal FC, 2009, BLOOD, V114, P5415, DOI 10.1182-blood-2008-10-182071; Hatefi Y, 1978, Methods Enzymol, V53, P27; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073-pnas.94.10.5302; Hirst J, 2008, BIOCHEM SOC T, V36, P976, DOI 10.1042-BST0360976; Jeanne M, 2010, CANCER CELL, V18, P88, DOI 10.1016-j.ccr.2010.06.003; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002-ijc.20424; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074-jbc.M611777200; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016-j.bbabio.2009.06.009; Martinvalet D, 2008, CELL, V133, P681, DOI 10.1016-j.cell.2008.03.032; Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038-nprot.2007.327; Nelson D, 2008, LEHNINGER PRINCIPLES, V1; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124-mol.106.030122; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016-j.febslet.2006.05.072; Papa S, 2008, BBA-BIOENERGETICS, V1777, P719, DOI 10.1016-j.bbabio.2008.04.005; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016-S0091-679X(08)62030-0; Quin J, 2005, J SURG RES, V127, P139, DOI 10.1016-j.jss.2005.01.014; Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200-JCO.2008.18.6130; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073-pnas.180290497; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016-j.cell.2004.05.008; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158-0008-5472.CAN-08-3722; Santana BAA, 2006, BRAZ J MED BIOL RES, V39, P615, DOI 10.1590-S0100-879X2006000500008; Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182-blood-2008-04-150250; Schmidt WJ, 2006, J NEURAL TRANSM-SUPP, P273; Tallman M, 2009, LEUKEMIA LYMPHOMA, V50, P12, DOI 10.1080-10428190802588360; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016-S0076-6879(96)64044-0; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038-sj.emboj.7600746; UYEMURA SA, 1992, INT J BIOCHEM, V24, P1743, DOI 10.1016-0020-711X(92)90123-I; Wang XF, 2010, ACTA PHARMACOL SIN, V31, P1604, DOI 10.1038-aps.2010.171; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182-blood-2007-07-102798; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085-jgp.8.6.519; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021-bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Yamamoto S, 2000, FREE RADICAL RES, V33, P407, DOI 10.1080-10715760000300941; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084-jem.181.5.1661; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126-science.1183424 |
dc.description.citedCount |
11 |
dc.description.citedTotWOSCount |
16 |
dc.description.citedWOSCount |
16 |
dc.format.extentCount |
10 |
dc.identifier.articleNo |
|
dc.identifier.coden |
LEUKE |
dc.identifier.pubmedID |
21869839 |
dc.identifier.scopusID |
84858001991 |
dc.identifier.url |
|
dc.publisher.address |
MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Leukemia |
dc.relation.ispartOfIssue |
3 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Leukemia |
dc.relation.ispartofPubTitleAbbr |
Leukemia |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
26 |
dc.source.ID |
WOS:000301290300010 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
α-tocopheryl succinate |
dc.subject.otherAuthKeyword |
acute promyelocytic leukemia |
dc.subject.otherAuthKeyword |
mitochondrial membrane potential |
dc.subject.otherAuthKeyword |
reactive oxygen species |
dc.subject.otherChemCAS |
alpha tocopherol succinate, 17407-37-3, 4345-03-3 |
dc.subject.otherChemCAS |
arsenic trioxide, 1303-24-8, 1327-53-3, 13464-58-9, 15502-74-6 |
dc.subject.otherChemCAS |
caspase, 186322-81-6 |
dc.subject.otherChemCAS |
cytochrome c, 9007-43-6, 9064-84-0 |
dc.subject.otherChemCAS |
retinoic acid, 302-79-4 |
dc.subject.otherChemCAS |
Antineoplastic Agents |
dc.subject.otherChemCAS |
Antioxidants |
dc.subject.otherChemCAS |
Arsenicals |
dc.subject.otherChemCAS |
Caspases, 3.4.22.- |
dc.subject.otherChemCAS |
Cytochromes c, 9007-43-6 |
dc.subject.otherChemCAS |
Electron Transport Complex I, 1.6.5.3 |
dc.subject.otherChemCAS |
Electron Transport Complex II, 1.3.5.1 |
dc.subject.otherChemCAS |
Oncogene Proteins, Fusion |
dc.subject.otherChemCAS |
Oxides |
dc.subject.otherChemCAS |
Reactive Oxygen Species |
dc.subject.otherChemCAS |
Tretinoin, 302-79-4 |
dc.subject.otherChemCAS |
alpha-Tocopherol, 59-02-9 |
dc.subject.otherChemCAS |
arsenic trioxide, 1327-53-3 |
dc.subject.otherChemCAS |
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein |
dc.subject.otherIndex |
alpha tocopherol succinate |
dc.subject.otherIndex |
arsenic trioxide |
dc.subject.otherIndex |
caspase |
dc.subject.otherIndex |
cytochrome c |
dc.subject.otherIndex |
reactive oxygen metabolite |
dc.subject.otherIndex |
retinoic acid |
dc.subject.otherIndex |
animal cell |
dc.subject.otherIndex |
animal experiment |
dc.subject.otherIndex |
animal model |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
cancer therapy |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
drug mechanism |
dc.subject.otherIndex |
drug tolerability |
dc.subject.otherIndex |
enzyme activation |
dc.subject.otherIndex |
enzyme release |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
human cell |
dc.subject.otherIndex |
in vivo study |
dc.subject.otherIndex |
mitochondrial membrane potential |
dc.subject.otherIndex |
mitochondrial respiration |
dc.subject.otherIndex |
mitochondrial targeting signal |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
promyelocytic leukemia |
dc.subject.otherIndex |
respiratory chain |
dc.subject.otherIndex |
transgenic mouse |
dc.subject.otherIndex |
alpha-Tocopherol |
dc.subject.otherIndex |
Animals |
dc.subject.otherIndex |
Antineoplastic Agents |
dc.subject.otherIndex |
Antioxidants |
dc.subject.otherIndex |
Apoptosis |
dc.subject.otherIndex |
Arsenicals |
dc.subject.otherIndex |
Caspases |
dc.subject.otherIndex |
Cell Line, Tumor |
dc.subject.otherIndex |
Cytochromes c |
dc.subject.otherIndex |
Disease Models, Animal |
dc.subject.otherIndex |
Electron Transport Complex I |
dc.subject.otherIndex |
Electron Transport Complex II |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Leukemia, Promyelocytic, Acute |
dc.subject.otherIndex |
Membrane Potential, Mitochondrial |
dc.subject.otherIndex |
Mice |
dc.subject.otherIndex |
Mice, Transgenic |
dc.subject.otherIndex |
Mitochondria |
dc.subject.otherIndex |
Neoplastic Stem Cells |
dc.subject.otherIndex |
Oncogene Proteins, Fusion |
dc.subject.otherIndex |
Oxides |
dc.subject.otherIndex |
Protein Stability |
dc.subject.otherIndex |
Rats |
dc.subject.otherIndex |
Reactive Oxygen Species |
dc.subject.otherIndex |
Transplantation, Isogeneic |
dc.subject.otherIndex |
Tretinoin |
dc.subject.otherKeywordPlus |
ALPHA-TOCOPHERYL SUCCINATE |
dc.subject.otherKeywordPlus |
VITAMIN-E SUCCINATE |
dc.subject.otherKeywordPlus |
PML-RAR-ALPHA |
dc.subject.otherKeywordPlus |
INDUCED APOPTOSIS |
dc.subject.otherKeywordPlus |
RETINOIC ACID |
dc.subject.otherKeywordPlus |
TUMOR-GROWTH |
dc.subject.otherKeywordPlus |
CANCER-CELL |
dc.subject.otherKeywordPlus |
MICE |
dc.subject.otherKeywordPlus |
APL |
dc.subject.otherKeywordPlus |
SUPEROXIDE |
dc.subject.otherWOS |
Oncology |
dc.subject.otherWOS |
Hematology |